Boston Scientific (BSX) announces an agreement to acquire Valencia Technologies Corporation; exp. to complete in H1'26 and have an immaterial impact to Adj. EPS

Boston Scientific's agreement to acquire Valencia Technologies Corporation, slated for completion in H1 2026, suggests a strategic expansion in their healthcare portfolio.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Bristol Myers Squibb (BMY) announces positive topline results from phase 3 SCOUT-HCM trials evaluating Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy

Newsquawk Daily US Conference Calendar - 12th January 2026: BMY, JNJ, BA, MCK, MSI, NKE, NOC

Boston Scientific (BSX) announces an agreement to acquire Valencia Technologies Corporation; exp. to complete in H1'26 and have an immaterial impact to Adj. EPS

Moderna (MRNA) 2025 revenue outlook of about USD 1.9bln (exp. USD 1.89bln) and improving 2025 expected GAAP operating expenses by USD 200mln to USD 5-5.2bln

EU Commission Spokesperson says that they stand ready to propose new and more severe sanctions on Iran

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

The expected immaterial impact on adjusted EPS indicates that while this acquisition may enhance their market position, it is not likely to significantly affect financial metrics in the near term. Traders should note the long-term potential and any further implications for the sector or competitive dynamics.

Related headlines

The whole workspace, free to try.

Try it free